HER-2 Expression in Immunohistochemistry Has No Prognostic Significance in Gastric Cancer Patients
The role of HER-2 expression as a prognostic factor in gastric cancer (GC) is still controversial. The aim of the study was to asses HER-2 status, its correlations with clinicopathological parameters, and prognostic impact in GC patients. Tumor samples were collected from 78 patients who had undergo...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1100/2012/941259 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832545674553458688 |
|---|---|
| author | Agnieszka Halon Piotr Donizy Przemyslaw Biecek Julia Rudno-Rudzinska Wojciech Kielan Rafal Matkowski |
| author_facet | Agnieszka Halon Piotr Donizy Przemyslaw Biecek Julia Rudno-Rudzinska Wojciech Kielan Rafal Matkowski |
| author_sort | Agnieszka Halon |
| collection | DOAJ |
| description | The role of HER-2 expression as a prognostic factor in gastric cancer (GC) is still controversial. The aim of the study was to asses HER-2 status, its correlations with clinicopathological parameters, and prognostic impact in GC patients. Tumor samples were collected from 78 patients who had undergone curative surgery. In order to evaluate the intensity of immunohistochemical (IHC) reactions two scales were applied: the immunoreactive score according to Remmele modified by the authors and standardised Hercep test score modified for GC by Hofmann et al. The HER-2 overexpression was detected by IHC in 23 (29.5%) tumors in Hercep test (score 2+/3+) and in 24 (30.7%) in IRS scale (IRS 4–12). The overexpression of HER-2 was associated with poorly differentiated tumors, but this correlation was not significant (P=0.064). No relationship was found between HER-2 expression and primary tumor size and degree of spread to regional lymph nodes. Both univariate and multivariate analyses revealed that TNM stage and patient’s age were the crucial negative prognostic factors. No correlation was observed between patient survival and expression of HER-2 estimated using both scales. This research did not confirm HER-2 expression (evaluated with immunohistochemistry) value as a prognostic tool in GC. |
| format | Article |
| id | doaj-art-d0e160cfbdab4d5f9f854a3ba42099c7 |
| institution | Kabale University |
| issn | 1537-744X |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-d0e160cfbdab4d5f9f854a3ba42099c72025-02-03T07:25:02ZengWileyThe Scientific World Journal1537-744X2012-01-01201210.1100/2012/941259941259HER-2 Expression in Immunohistochemistry Has No Prognostic Significance in Gastric Cancer PatientsAgnieszka Halon0Piotr Donizy1Przemyslaw Biecek2Julia Rudno-Rudzinska3Wojciech Kielan4Rafal Matkowski5Department of Pathomorphology, Wroclaw Medical University, ul. Marcinkowskiego 1, 50-368 Wroclaw, PolandDepartment of Pathomorphology, Wroclaw Medical University, ul. Marcinkowskiego 1, 50-368 Wroclaw, PolandFaculty of Mathematics, Informatics and Mechanics, University of Warsaw, Krakowskie Przedmieście 26/28, 00-927 Warsaw, PolandDepartment of General and Oncological Surgery, Wroclaw Medical University, ul. Borowska 213, 50-556 Wroclaw, PolandDepartment of General and Oncological Surgery, Wroclaw Medical University, ul. Borowska 213, 50-556 Wroclaw, PolandDepartment of Oncology, Wroclaw Medical University, Plac Hirszfelda 12, 53-413 Wroclaw, PolandThe role of HER-2 expression as a prognostic factor in gastric cancer (GC) is still controversial. The aim of the study was to asses HER-2 status, its correlations with clinicopathological parameters, and prognostic impact in GC patients. Tumor samples were collected from 78 patients who had undergone curative surgery. In order to evaluate the intensity of immunohistochemical (IHC) reactions two scales were applied: the immunoreactive score according to Remmele modified by the authors and standardised Hercep test score modified for GC by Hofmann et al. The HER-2 overexpression was detected by IHC in 23 (29.5%) tumors in Hercep test (score 2+/3+) and in 24 (30.7%) in IRS scale (IRS 4–12). The overexpression of HER-2 was associated with poorly differentiated tumors, but this correlation was not significant (P=0.064). No relationship was found between HER-2 expression and primary tumor size and degree of spread to regional lymph nodes. Both univariate and multivariate analyses revealed that TNM stage and patient’s age were the crucial negative prognostic factors. No correlation was observed between patient survival and expression of HER-2 estimated using both scales. This research did not confirm HER-2 expression (evaluated with immunohistochemistry) value as a prognostic tool in GC.http://dx.doi.org/10.1100/2012/941259 |
| spellingShingle | Agnieszka Halon Piotr Donizy Przemyslaw Biecek Julia Rudno-Rudzinska Wojciech Kielan Rafal Matkowski HER-2 Expression in Immunohistochemistry Has No Prognostic Significance in Gastric Cancer Patients The Scientific World Journal |
| title | HER-2 Expression in Immunohistochemistry Has No Prognostic Significance in Gastric Cancer Patients |
| title_full | HER-2 Expression in Immunohistochemistry Has No Prognostic Significance in Gastric Cancer Patients |
| title_fullStr | HER-2 Expression in Immunohistochemistry Has No Prognostic Significance in Gastric Cancer Patients |
| title_full_unstemmed | HER-2 Expression in Immunohistochemistry Has No Prognostic Significance in Gastric Cancer Patients |
| title_short | HER-2 Expression in Immunohistochemistry Has No Prognostic Significance in Gastric Cancer Patients |
| title_sort | her 2 expression in immunohistochemistry has no prognostic significance in gastric cancer patients |
| url | http://dx.doi.org/10.1100/2012/941259 |
| work_keys_str_mv | AT agnieszkahalon her2expressioninimmunohistochemistryhasnoprognosticsignificanceingastriccancerpatients AT piotrdonizy her2expressioninimmunohistochemistryhasnoprognosticsignificanceingastriccancerpatients AT przemyslawbiecek her2expressioninimmunohistochemistryhasnoprognosticsignificanceingastriccancerpatients AT juliarudnorudzinska her2expressioninimmunohistochemistryhasnoprognosticsignificanceingastriccancerpatients AT wojciechkielan her2expressioninimmunohistochemistryhasnoprognosticsignificanceingastriccancerpatients AT rafalmatkowski her2expressioninimmunohistochemistryhasnoprognosticsignificanceingastriccancerpatients |